What happened

Honasa Consumer — the company behind Mamaearth and The Derma Co — hit a fresh 52-week high of ₹501.55 this morning, up about 5% intra-day on the BSE, after it posted its June-quarter (Q1FY27) results. The buying was real, not a whisper: trading volume jumped more than 15-fold, with about 6.7 million shares changing hands across the NSE and BSE by mid-morning. The stock has now more than doubled — up 102% — from its 52-week low of ₹248.55 hit in December 2025.

Why it moved

This was a clean beat driven by the actual business, not a one-off. Honasa reported its highest-ever quarterly revenue of ₹785 crore, up 31.8% year-on-year, and the growth was led by volumes — meaning it sold more product, not just raised prices. Profit after tax jumped 118% YoY to ₹90.3 crore, also a record. The bit that got the market excited is margins: adjusted EBITDA more than doubled, and the EBITDA margin widened by 538 basis points to 13.1%, as higher-margin lines like facewash and serums took a bigger share of the mix. In plain terms, Honasa is finally showing it can grow fast and make money at the same time — the exact thing investors had been waiting for. Management guided to another 100–150 bps of margin expansion in FY27 (off a ~10% base in FY26), and brokerages nudged up their FY27–29 earnings estimates by 15–19% after the print.

Is it expensive?

Short answer: yes, in absolute terms. Honasa trades at a P/E in the mid-to-high 70s on a market cap of roughly ₹15,700 crore (Screener / valuation trackers). A multiple like that already prices in years of fast growth — there's very little cushion for a stumble. For context, Marico, a far larger and steadier FMCG name, trades near 55x; so Honasa is meaningfully pricier than the established incumbent. But it's still cheaper than fellow digital-first peer Nykaa (FSN E-Commerce), whose P/E runs into the triple digits. So Honasa sits squarely in the "expensive growth" bucket — a 118% profit jump and 30%+ volume-led growth are precisely what a valuation this rich demands, not a bonus.

The business

Honasa isn't a one-product story. It's India's largest digital-first beauty-and-personal-care (BPC) company, running a house of seven brands: Mamaearth (the mass-market flagship), The Derma Co (science-led skincare), Aqualogica, Dr. Sheth's, BBlunt, Ayuga and Staze. That spread matters for reading today's number. Mamaearth grew in the high teens this quarter, while the younger brands grew ~40% YoY — and The Derma Co crossed a ₹1,000 crore annualised run-rate with double-digit EBITDA margins. So the re-rating is being carried by the newer, faster brands, not just the flagship.

Who it touches

• Legacy FMCG/BPC (HUL, Marico, Dabur, Emami, Godrej Consumer): a challenger taking share in facewash, serums and shampoo raises the competitive heat in exactly their high-margin categories.
• Other new-age consumer names (Nykaa and D2C peers): Honasa proving the "grow fast and profitable" model works is a positive read-through for the whole digital-first theme.
• E-commerce and quick-commerce rails (Nykaa, Amazon, Blinkit/Zepto): these are the distribution highways Honasa's brands ride on.

What to watch

The one thing that could flip the story: gross margin actually fell 150 bps YoY to 69.7% on higher packaging costs. Today's margin cheer came from operating leverage lower down, not from the product itself getting cheaper to make. If input and packaging costs keep climbing, or if ad spend has to rise to hold 30%+ growth, the margin-expansion narrative driving this re-rating could stall — and at a P/E in the 70s, the market won't forgive a miss quietly. Watch whether Mamaearth (the biggest brand, only high-teens growth) can re-accelerate, and whether that FY27 margin guidance actually lands.

As of ~11:00 AM IST, 14 Aug 2026. Sources: Business Standard, Screener.in. For discussion and education only — not investment advice. Verify before acting.